• 5분 읽기
• 2026년 1월 7일 게시
안녕하세요! 저희는 Nemo입니다.
Nemo는 'Never Miss Out(기회를 놓치지 마세요)'의 약자로, 데이터 기반으로 엄선한 투자 아이디어를 손안에서 바로 확인할 수 있는 모바일 투자 플랫폼입니다. 주식, ETF, 암호화폐, CFD를 수수료 없이 거래할 수 있으며, AI 기반 도구, 실시간 시장 알림, 그리고 Nemes라고 불리는 테마별 주식 컬렉션을 제공합니다.
앱 다운로드
QR 코드를 스캔하여 Nemo 앱을 다운로드하고 지금 바로 Nemo에서 투자를 시작하세요
2026년 9월 14일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 13일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
Every now and then, a headline cuts through the usual market noise and forces even a jaded old cynic like me to sit up and pay attention. Regeneron announcing a 100% complete response rate in a lymphoma trial was one of those moments. One hundred percent. In medicine, and especially in oncology, you just don’t see that number. It sounds more like a dictator’s election results than a clinical trial outcome. But here we are.
This isn’t just another small step forward. To me, it feels like a different game entirely. It signals that the field of immuno-oncology, long touted as the future, might finally be delivering on its rather grand promises. For investors, this kind of news is both thrilling and terrifying. Thrilling because of the sheer potential, and terrifying because biotech is a notorious graveyard for capital.
So, what is this miracle cure? At its heart is something called a bispecific antibody. Forget the jargon. Think of it like a highly specialised molecular matchmaker. Traditional chemotherapy is a bit of a brute, a sledgehammer that smashes cancer cells but often takes a lot of healthy ones with them. It’s effective, but messy. Immuno-oncology is far more elegant.
These new therapies don’t attack the cancer directly. Instead, they grab one of your body’s own immune cells by the hand, drag it over to a cancer cell, and say, "Right, you see this chap? He's not supposed to be here. Do your job". By physically connecting the hunter to the hunted, it unleashes the full, targeted power of your immune system. Regeneron’s result suggests this matchmaking service is exceptionally good at its job. The implications are enormous, potentially shifting cancer treatment from a war of attrition to a precision strike.
Of course, Regeneron isn’t the only player in this sophisticated new game. You have companies like Moderna, famous for its COVID jab, now applying that same mRNA technology to create personalised cancer vaccines. They essentially take a mugshot of a patient’s unique tumour and create a bespoke vaccine to train the immune system to hunt it down. It’s the Savile Row of cancer treatment.
Then there’s Gilead, which is pioneering a different route with CAR T-cell therapy. This involves taking a patient’s own immune cells out of their body, genetically re-engineering them in a lab to be better cancer killers, and then putting them back in. It’s complex, it's expensive, but for some blood cancers, the results have been nothing short of miraculous. The sheer variety of these approaches shows just how much intellectual and financial firepower is being aimed at this problem. It begs the question for anyone with a bit of risk appetite, when it comes to Cancer Therapies: What's Next After 100% Response Rate, where does one even begin?
Let's be clear. Investing in individual biotech firms is not for the faint of heart. For every Regeneron, there are a dozen companies whose promising drugs fail in late-stage trials, taking shareholder fortunes with them. A single clinical setback can wipe out a company’s value overnight. It’s a high-stakes game of scientific and regulatory roulette.
This is why, for most people, a thematic approach makes a great deal more sense. Instead of betting the farm on a single company’s miracle cure, you can spread your investment across a basket of the leading innovators. You get exposure to the bispecific antibodies, the mRNA vaccines, and the cellular therapies all at once. It’s a way of participating in the revolution without being entirely dependent on one particular battle turning out right. By diversifying, you smooth out the terrifying volatility of the sector while keeping a stake in what could be one of the most important medical advances of our lifetime.
전체 바스켓 보기:Cancer Therapies: What's Next After 100% Response Rate
본 기사는 마케팅 자료이며 투자 조언으로 해석되어서는 안 됩니다. 본 기사에 포함된 어떠한 정보도 금융 상품의 매수 또는 매도에 대한 조언, 추천, 제안 또는 권유로 간주되어서는 안 되며, 금융, 투자 또는 거래 조언에 해당하지 않습니다. 특정 금융 상품이나 투자 전략에 대한 언급은 예시 및 교육 목적으로만 제공되며 사전 통지 없이 변경될 수 있습니다. 투자 예정 대상을 평가하고, 본인의 재무 상황을 검토하고, 독립적인 전문가의 조언을 구하는 것은 투자자 본인의 책임입니다. 과거의 성과가 미래의 결과를 보장하지 않습니다. 자세한 내용은 다음 문서를 참조하십시오: 리스크 고지.
2026년 9월 14일 게시
기사 읽기
2026년 9월 14일 게시
기사 읽기
2026년 9월 13일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기
2026년 9월 12일 게시
기사 읽기